- Home
- DRUG
DRUG
Bright Minds Biosciences Inc.
as 04-18-2025 1:35pm EST
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | $84.33 | AVG Volume (30 days): | 32.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.93 - $79.02 | Next Earning Date: | 05-16-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Bright Minds Biosciences Inc. News
DRUG Breaking Stock News: Dive into DRUG Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
GlobeNewswire
2 months ago
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
GlobeNewswire
3 months ago
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire
5 months ago
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
TipRanks
5 months ago
Bright Minds Biosciences Secures $35 Million Investment
GlobeNewswire
5 months ago
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
GlobeNewswire
6 months ago
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
GlobeNewswire
6 months ago
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
Compare DRUG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DRUG Bright Minds Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.